MedTrace Logo

Ethosomal Gel Bearing Losartan 5% for Keloid Treatment

NCT05893108 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-12-05

No results posted yet for this study

Summary

The objectives are to compare the efficacy of pre and post-treatment and between 5% losartan potassium loaded in ethosomal gel and 10 mg/ml triamcinolone acetonide injection based on the indicator score of The patient and observer scar assessment scale 3.0 (POSAS 3.0), degree of erythema and pigmentation, area size, thickness and density of human keloids.

Conditions

  • Keloid

Interventions

DRUG

Ethosomal gel bearing losartan 5%

A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%

DRUG

triamcinolone acetonide 10 mg/ml

intralesional injection

Sponsors & Collaborators

  • Gadjah Mada University

    collaborator OTHER

  • Yuni Eka Anggraini

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2024-09-30
Completion
2024-10-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893108 on ClinicalTrials.gov